Albinterferon alfa-2b - Novartis
Alternative Names: ABF 656; Albuferon; Albuferon-α; Albumin-interferon alfa; Albumin/interferon-alpha fusion protein - Human Genome Sciences/Novartis; Interferon-alpha/albumin fusion protein - Human Genome Sciences/Novartis; Joulferon; ZalbinLatest Information Update: 24 Oct 2021
At a glance
- Originator Human Genome Sciences
- Developer Human Genome Sciences; Novartis
- Class Albumins; Antineoplastics; Antivirals; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
- 06 Oct 2010 Discontinued - Phase-I for Hepatitis C in Japan (SC)
- 06 Oct 2010 Discontinued - Phase-I/II for Hepatitis B in Asia (SC)